89 related articles for article (PubMed ID: 20716886)
21. Anastrozole for breast cancer: recent advances and ongoing challenges.
Buzdar AU
Expert Rev Anticancer Ther; 2006 Jun; 6(6):839-48. PubMed ID: 16761927
[TBL] [Abstract][Full Text] [Related]
22. Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer.
Arun B; Valero V; Liu D; Brewster A; Green M; Gutierrez-Barrera A; Akar U; Rivera E; Esteva FJ; Buzdar AU; Hortobagyi GN; Sneige N
Cancer Prev Res (Phila); 2012 Feb; 5(2):276-82. PubMed ID: 22102688
[TBL] [Abstract][Full Text] [Related]
23. ARIMIDEX: a potent and selective aromatase inhibitor for the treatment of advanced breast cancer.
Buzdar AU; Jonat W; Howell A; Plourde PV
J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):145-9. PubMed ID: 9365184
[TBL] [Abstract][Full Text] [Related]
24. Estrogen receptors evolution in neoadjuvant aromatase inhibitor (AI) therapy for breast cancer in elderly women: stability of hormonal receptor expression during treatment.
Salmon RJ; Alran S; Malka I; de Cremoux P; Rosty C; Languille O; Campana F; ; Sigal-Zafrani B
Am J Clin Oncol; 2006 Aug; 29(4):385-8. PubMed ID: 16891867
[TBL] [Abstract][Full Text] [Related]
25. [An elderly patient with advanced breast cancer who responded to treatment with letrozole-a case report].
Yoneyama K; Nakamura H
Gan To Kagaku Ryoho; 2013 Dec; 40(13):2565-7. PubMed ID: 24335371
[TBL] [Abstract][Full Text] [Related]
26. [Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer].
Bergmann L
Strahlenther Onkol; 2001 May; 177(5):273-4. PubMed ID: 11398617
[No Abstract] [Full Text] [Related]
27. [Endometrial stromal sarcoma: complete response to therapy with aromatase-inhibitor, anastrozole].
Lisianskaia AS; Manikhas GM; Fadeeva EP; Fedosenko KV; Tapil'skaia NI
Vopr Onkol; 2010; 56(1):91-3. PubMed ID: 20361625
[No Abstract] [Full Text] [Related]
28. Focus on anastrozole and breast cancer.
Mokbel K
Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
[TBL] [Abstract][Full Text] [Related]
29. Hemicentral retinal artery occlusion in a breast cancer patient using anastrozole.
Karagöz B; Ayata A; Bilgi O; Uzun G; Unal M; Kandemir EG; Ozgün A; Türken O
Onkologie; 2009 Jul; 32(7):421-3. PubMed ID: 19556821
[TBL] [Abstract][Full Text] [Related]
30. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
[TBL] [Abstract][Full Text] [Related]
31. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
Buzdar AU; Cuzick J
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1037s-1048s. PubMed ID: 16467122
[TBL] [Abstract][Full Text] [Related]
32. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J;
Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253
[TBL] [Abstract][Full Text] [Related]
33. Anastrozole data show continued delay in relapse, but no clear survival advantage.
Travis K
J Natl Cancer Inst; 2005 Jan; 97(2):86-7. PubMed ID: 15657334
[No Abstract] [Full Text] [Related]
34. Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer.
Kristensen VN; Sørlie T; Geisler J; Yoshimura N; Linegjaerde OC; Glad I; Frigessi A; Harada N; Lønning PE; Børresen-Dale AL
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):105-11. PubMed ID: 16023338
[TBL] [Abstract][Full Text] [Related]
35. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
Howell A; Cuzick J; Baum M; Buzdar A; Dowsett M; Forbes JF; Hoctin-Boes G; Houghton J; Locker GY; Tobias JS;
Lancet; 2005 Jan 1-7; 365(9453):60-2. PubMed ID: 15639680
[TBL] [Abstract][Full Text] [Related]
36. Drug-induced pruritic micropapular eruption: anastrozole, a commonly used aromatase inhibitor.
Bremec T; Demsar J; Luzar B; Pavlović MD
Dermatol Online J; 2009 Jul; 15(7):14. PubMed ID: 19903442
[TBL] [Abstract][Full Text] [Related]
37. Aromatase inhibitors in the treatment of early and advanced breast cancer.
Joensuu H; Ejlertsen B; Lønning PE; Rutqvist LE
Acta Oncol; 2005; 44(1):23-31. PubMed ID: 15848903
[TBL] [Abstract][Full Text] [Related]
38. [Long-Term Effect of Fulvestrant for Locally Advanced Breast Cancer in an Elderly Patient - A Case Report].
Sakurai K; Fujisaki S; Kubota H; Hara Y; Suzuki S; Adachi K; Tomita R; Enomoto K; Hirano T
Gan To Kagaku Ryoho; 2018 Jan; 45(1):76-78. PubMed ID: 29362313
[TBL] [Abstract][Full Text] [Related]
39. [A case of aromatase inhibitor-tolerant metastatic breast cancer revealing complete remission with high-dose toremifene therapy].
Kurozumi S; Takeo T; Ikeda F; Horiguchi J; Takeyoshi I; Ito H
Gan To Kagaku Ryoho; 2011 Jan; 38(1):93-6. PubMed ID: 21368465
[TBL] [Abstract][Full Text] [Related]
40. Anastrozole. An effective, second-line hormonal treatment for advanced breast cancer.
Camp-Sorrell D
Cancer Pract; 1997; 5(6):391-3. PubMed ID: 9397709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
